Emerging technologies are reshaping diagnosis and treatment of infectious and metabolic conditions. B7-H3 targeted antibody-drug conjugate ICP-B794 received IND clearance in China, advancing immuno-oncology options. Doxycycline used as pre-exposure prophylaxis alters microbiomes in HIV-prEP populations, highlighting complex impacts on STI prevention strategies. Novel nucleoside prodrugs discovered by Shanghai Curegene demonstrate antiviral potential. On the metabolic front, THR-123, an ALK3 receptor agonist, promotes pancreatic β-cell regeneration with implications for diabetes therapy.